Recent Updates
Recently added Catalysts
BBNX Negative Sentiment Score: 30/100

Beta Bionics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

Key Takeaway: Johnson Fistel, PLLP is conducting an investigation into Beta Bionics, Inc. concerning potential violations of federal securities laws related to reported investor losses. This follows the company's recent disclosure, which revealed a lower-than-expected growth in new patient starts and resulted in a significant drop in stock price. Investors concerned about their losses are encouraged to contact Johnson Fistel for more information on the investigation and recovery possibilities.

Market Sentiment Analysis

CONCERNS & RISKS

  • Beta Bionics issued preliminary financial results showing slower growth in new patient starts.
  • The stock price of Beta Bionics declined more than 35% following the disappointing announcement.
  • The ongoing investigation into potential violations of federal securities laws raises uncertainties for shareholders.

Full Press Release Details

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
What if I purchased Beta Bionics securities?
If you purchased Beta Bionics securities and suffered losses on your investment, join our investigation now: Click Here to Join the Investigation.
Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.
Background of the Investigation
On January 8, 2026, Beta Bionics issued preliminary, unaudited fourth quarter 2025 topline financial results and key operating metrics. The Company reported that new patient starts for the quarter were expected to be at least 5,581, representing year-over-year growth of at least 36%. The reported figure was below analyst expectations and reflected a slowdown from the prior quarter, when Beta Bionics reported 68% year-over-year growth in new patient starts.
Following the announcement, Beta Bionics’ stock price declined more than 35% on January 9, 2026.
In light of this disclosure, Johnson Fistel is investigating whether Beta Bionics complied with federal securities laws. If you suffered losses, contact Johnson Fistel for more information.
About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder class actions and derivative lawsuits. Johnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. In 2024, the firm recovered approximately $90,725,000 for investors.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
James Baker, Investor Relations – or – Frank J. Johnson, Esq.

Tags

Frequently Asked Questions

What is Johnson Fistel investigating regarding Beta Bionics?

They are investigating potential violations of federal securities laws by Beta Bionics.

What triggered the investigation into Beta Bionics?

A stock price drop of over 35% following their fourth quarter 2025 financial results.

How can I join the investigation if I suffered losses?

Contact Johnson Fistel or click the provided link to join the investigation.

Does it cost anything to join the investigation?

There is no cost or obligation to join the investigation.

Who should I contact for more information?

You can reach out to Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.

Last updated: Jun 1, 2026